Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Needham Keeps Underperform on Atherogenics

Needham reiterated its underperform rating on Atherogenics (AGIX), saying it's not impressed by recent Phase 2B data.

Analyst Mark Monane says he questions the quality of data and interim, subgroup analysis in the company's Phase 2b trial of AGI-1067 anti-inflammatory agent. He says the data suggest the drug is biologically active, but gives him no added confidence in Phase 3 trial currently underway. He does not understand why full "intention to treat" data were not available in Phase 2b trial. He notes analysis methodology is out of the ordinary, with data sets coming from two difference sites.

Monane thinks the analysis applied to date do not support the stock's current valuation. He sees $1.82 2004 loss per share and $1.77 2005 loss.

blog comments powered by Disqus